16 results on '"Leiter, Lawrence A."'
Search Results
2. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
3. †Efficacy and Safety of Inclisiran in Patients with Established Cerebrovascular Disease: Pooled Post hoc Analysis of the Phase 3 ORION-9, ORION-10, and ORION-11 Randomized Controlled Trials
4. †Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled Post hoc Analysis of the phase 3 ORION-9, ORION-10, and ORION-11 Randomized Controlled Trials
5. Long-Term Efficacy and Safety of Twice-Yearly Inclisiran in Patients with ASCVD and Elevated LDL-C: A Post-Hoc Analysis of ORION-3, a 4-year Open-Label Extension Study
6. Bempedoic Acid and Glycemic Control: A Pooled Analysis of 4 Phase 3 Clinical Trials
7. Bempedoic Acid Efficacy and Safety in High CVD Risk Patients Treated With or Without Ezetimibe: Pooled Analysis of 4 Phase 3 Clinical Trials†
8. Efficacy and Safety of Bempedoic Acid in Elderly Patients: Pooled Analyses from Phase 3 Trials
9. Alirocumab Treatment Effect on Non-HDL-C: Pooled Analyses of 10 Phase 3 Trials in the ODYSSEY Program
10. Greater Dissociation of Apolipoprotein B and LDL Cholesterol Targets in Diabetes Versus Nondiabetes Patients Receiving Lipid-Lowering Therapy
11. Lower LDL-C values Should Be Reached to Normalize Apolipoprotein B Concentrations in Hypertriglyceridemic Patients Receiving Lipid-lowering Therapy
12. Dissociation of Apolipoprotein B, Low-Density Lipoprotein Cholesterol, and Non-High-Density Lipoprotein Cholesterol Targets in Patients Receiving Lipid
13. Effect of Ezetimibe Added to Atorvastatin on Lipoprotein Subclass Cholesterol Content in Patients with Higher Versus Lower Triglyceride Levels
14. Comparative Efficacy of Ezetimibe Added to Atorvastatin vs. Uptitration of Atorvastatin in Attainment of Recommended Lipid Targets in Patients at High Risk for Coronary Heart Disease
15. Do Age, Gender, and Race Affect the Efficacy of Ezetimibe Plus Atorvastatin vs. Doubling the Atorvastatin Dose in Moderately High and High CHD Risk Patients?
16. Does Baseline Body Mass Index, Fasting Blood Sugar, and High-Sensitivity C-Reactive Protein Influence the Efficacy of Adding Ezetimibe to Atorvastatin Versus Doubling the Atorvastatin Dose in Moderately High and High Coronary Heart Disease Risk Patients?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.